Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma

Cutaneous squamous cell carcinoma is the second most prevalent malignancy, most frequently occurring in the head and neck (head and neck cutaneous squamous cell carcinoma). Treatment of locally advanced or metastatic disease is associated with functional morbidity and disfigurement. Underlying genetic mechanisms are poorly understood. Targeted sequencing of 48 clinically relevant genes was performed on DNA extracted from formalin-fixed and paraffin-embedded high-risk primary head and neck cutaneous squamous cell carcinomas that remained non-metastatic at minimum follow-up of 24 months. Associations of somatic mutations with clinicopathologic characteristics were evaluated and compared with those described in the literature for metastatic disease. Alterations in 44 cancer-associated genes were identified. TP53 was mutated in 100% of cases; APC, ATM, ERBB4, GNAQ, KIT, RB1 and ABL1 were altered in 60% of cases. FGFR2 mutations (40%) were exclusively seen in patients with perineural invasion. MLH1 mutations were exclusively seen in the two younger patients (<45 years). Lower incidences of NOTCH1 mutations were observed compared with that described in metastatic head and neck cutaneous squamous cell carcinoma in the literature. Somatic mutations susceptible to EGFR inhibitors, and other small molecular targeted therapeutics were seen in 60% of cases. This study provides insights into somatic mutations in non-metastatic, high-risk head and neck cutaneous squamous cell carcinoma and identifies potential therapeutic targets. Alterations in FGFR2 and NOTCH1 may have roles in local and distant disease progression.

[1]  W. Travis,et al.  New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Ghilsuk Yoon,et al.  Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status , 2016, Tumor Biology.

[3]  C. Deng,et al.  Smad 4 Loss Causes Spontaneous Head and Neck Cancer with Increased Genomic Instability and Inflammation , 2009 .

[4]  S. W. Han,et al.  Identification of a Novel Pathogenic Germline KDR Variant in Melanoma , 2015, Clinical Cancer Research.

[5]  Curtis R. Pickering,et al.  Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma , 2014, Clinical Cancer Research.

[6]  T. Yen,et al.  Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma , 2016, Oncotarget.

[7]  Graham G Giles,et al.  Non‐melanoma skin cancer in Australia: the 2002 national survey and trends since 1985 , 2006, The Medical journal of Australia.

[8]  Jean Y. Tang,et al.  Smoothened variants explain the majority of drug resistance in basal cell carcinoma. , 2015, Cancer cell.

[9]  E. Decullier,et al.  Sirolimus and secondary skin-cancer prevention in kidney transplantation. , 2012, The New England journal of medicine.

[10]  K. Purdie,et al.  Cutaneous Squamous Cell Carcinoma (SCC) and the DNA Damage Response: pATM Expression Patterns in Pre-Malignant and Malignant Keratinocyte Skin Lesions , 2011, PloS one.

[11]  M. Meyerson,et al.  PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. , 2009, Cancer research.

[12]  R. Tarone,et al.  Frequent clones of p53-mutated keratinocytes in normal human skin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. Schönfisch,et al.  Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. , 2008, The Lancet. Oncology.

[14]  M. Varvares,et al.  Evaluation of the Definitions of “High-Risk” Cutaneous Squamous Cell Carcinoma Using the American Joint Committee on Cancer Staging Criteria and National Comprehensive Cancer Network Guidelines , 2014, Journal of skin cancer.

[15]  David E. Fisher,et al.  The melanoma revolution: From UV carcinogenesis to a new era in therapeutics , 2014, Science.

[16]  P. Hammerman,et al.  Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma , 2015, Clinical Cancer Research.

[17]  H. Grabsch,et al.  FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study , 2014, British Journal of Cancer.

[18]  D. Aebersold,et al.  KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells , 2015, Molecular oncology.

[19]  Chien-Feng Li,et al.  Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy , 2014, Journal of Clinical Pathology.

[20]  M. Stratton,et al.  High burden and pervasive positive selection of somatic mutations in normal human skin , 2015, Science.

[21]  M. Chambers,et al.  A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck , 2012, Clinical Cancer Research.

[22]  M. Fortini,et al.  Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. , 2012, Seminars in cell & developmental biology.

[23]  Mi-Yeon Kim,et al.  Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. , 2002, Journal of dermatological science.

[24]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[25]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[26]  P. Petrow,et al.  Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Sung,et al.  Twist1 is a key regulator of cancer-associated fibroblasts. , 2015, Cancer research.

[28]  M. Jaworska,et al.  PTEN as a Prognostic and Predictive Marker in Postoperative Radiotherapy for Squamous Cell Cancer of the Head and Neck , 2012, PloS one.

[29]  B. Bastian,et al.  KIT as a therapeutic target in melanoma. , 2010, The Journal of investigative dermatology.

[30]  Jian Li,et al.  Temporal dissection of tumorigenesis in primary cancers. , 2011, Cancer discovery.

[31]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[32]  M. Ponz de Leòn,et al.  Muir-Torre syndrome. , 2005, The Lancet. Oncology.

[33]  L. Zou,et al.  DNA damage sensing by the ATM and ATR kinases. , 2013, Cold Spring Harbor perspectives in biology.

[34]  J. Platt,et al.  Dimerization of MLH1 and PMS2 Limits Nuclear Localization of MutLα , 2003, Molecular and Cellular Biology.

[35]  S Ichii,et al.  Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. , 1992, Human molecular genetics.

[36]  J. Reichrath,et al.  Notch-signaling and nonmelanoma skin cancer: an ancient friend, revisited. , 2012, Advances in experimental medicine and biology.

[37]  Chang Yu,et al.  Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer , 2014, Gut.

[38]  S. Arron,et al.  NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis , 2014, The Journal of investigative dermatology.

[39]  M. Mohammadi,et al.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. , 2007, Molecular cell.

[40]  P. Stephens,et al.  Evaluation of 122 advanced‐stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies , 2016, Cancer.

[41]  Jonathan R. Clark,et al.  Assessment of the new nodal classification for cutaneous squamous cell carcinoma and its effect on patient stratification , 2015, Head & neck.

[42]  N. Baker,et al.  Cutaneous squamous cell carcinoma of the head and neck , 1996 .

[43]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[44]  Tom R. Gaunt,et al.  Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov Models , 2012, Human mutation.

[45]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[46]  I. Wistuba,et al.  Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. , 2013, Lung cancer.

[47]  P. Pollock,et al.  FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features , 2012, PloS one.

[48]  A. Sarasin,et al.  The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. , 2005, Mutation research.

[49]  W. Chan,et al.  Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Jiro Shimada,et al.  In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras–effector interaction , 2013, Proceedings of the National Academy of Sciences.